- Home
- FSBC vs TYRA Comparison
FSBC vs TYRA Comparison
Compare FSBC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSBC
- TYRA
- Stock Information
- Founded
- FSBC 2002
- TYRA 2018
- Country
- FSBC United States
- TYRA United States
- Employees
- FSBC N/A
- TYRA N/A
- Industry
- FSBC Banks
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- FSBC Finance
- TYRA Health Care
- Exchange
- FSBC Nasdaq
- TYRA Nasdaq
- Market Cap
- FSBC 565.6M
- TYRA 580.2M
- IPO Year
- FSBC 2021
- TYRA 2021
- Fundamental
- Price
- FSBC $30.59
- TYRA $11.15
- Analyst Decision
- FSBC Buy
- TYRA Strong Buy
- Analyst Count
- FSBC 5
- TYRA 7
- Target Price
- FSBC $34.80
- TYRA $30.86
- AVG Volume (30 Days)
- FSBC 38.9K
- TYRA 251.5K
- Earning Date
- FSBC 07-23-2025
- TYRA 08-11-2025
- Dividend Yield
- FSBC 2.62%
- TYRA N/A
- EPS Growth
- FSBC 2.43
- TYRA N/A
- EPS
- FSBC 2.44
- TYRA N/A
- Revenue
- FSBC $132,133,000.00
- TYRA N/A
- Revenue This Year
- FSBC $26.05
- TYRA N/A
- Revenue Next Year
- FSBC $15.06
- TYRA N/A
- P/E Ratio
- FSBC $12.53
- TYRA N/A
- Revenue Growth
- FSBC 18.01
- TYRA N/A
- 52 Week Low
- FSBC $22.22
- TYRA $6.42
- 52 Week High
- FSBC $35.13
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- FSBC 56.91
- TYRA 59.64
- Support Level
- FSBC $29.56
- TYRA $10.71
- Resistance Level
- FSBC $31.40
- TYRA $11.23
- Average True Range (ATR)
- FSBC 0.87
- TYRA 0.67
- MACD
- FSBC -0.03
- TYRA 0.06
- Stochastic Oscillator
- FSBC 56.10
- TYRA 69.91
About FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.